Health - Diabetes latest news

Nanotherapeutics, a privately held specialty biopharmaceutical company, announced that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOXT Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomized double-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcers of the lower extremity.

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced that the company held a successful End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) on August 29, 2008. Following a review of the Phase II data on Microcyn® Technology for the treatment of mildly infected diabetic foot ulcers, the FDA agreed: - Oculus may move forward into the pivotal phase of its U.S. clinical program for Microcyn Technology.

Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention (PCI) with the CYPHER® Sirolimus-eluting Coronary Stent was comparable to bypass surgery (coronary artery bypass grafting or CABG) in key safety endpoints in patients with multi-vessel disease and diabetes. These data were presented here recently at the European Society of Cardiology meeting.